Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands

被引:19
作者
Alfian, Sofa D. [1 ,2 ]
Worawutputtapong, Pawida [1 ]
Schuiling-Veninga, Catharina C. M. [1 ]
van der Schans, Jurjen [1 ]
Bos, Jens H. J. [1 ]
Hak, Eelko [1 ]
Denig, Petra [3 ]
机构
[1] Univ Groningen, Groningen Res Inst Pharm, Unit PharmacoTherapy Epidemiol & Econ, POB 196, NL-9700 AD Groningen, Netherlands
[2] Univ Padjadjaran, Dept Pharmacol & Clin Pharm, Fac Pharm, Jawa Barat, Indonesia
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
关键词
Medication adherence; diabetes mellitus; hydroxymethylglutaryl-CoA reductase inhibitors; CHOLESTEROL RESPONSE; ADHERENCE; DISCONTINUATION; CARE; THERAPY;
D O I
10.1080/03007995.2017.1417242
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To evaluate statin non-persistence and non-adherence as discrete processes in diabetes patients, and identify pharmacy-based predictors of these processes in the first year after statin initiation. Methods: We conducted a retrospective cohort study of statin initiators using a pharmacy database. Persistence and adherence were measured in the first, second and third year. Non-persistence was defined as a gap > 180 days. Non-adherence was calculated in persistent patients and defined as a medication possession ratio < 80%. Cox regression hazard ratios (HRs) and logistic regression odds ratios (ORs) were assessed for sociodemographic and medication-related factors as possible predictors. Results: Of 12,741 initiators, 20.0% were non-persistent in the first year, while 9.0% and 7.5% were non-persistent in the second and third years. Non-adherence in persistent patients increased from 13.4% in the first to 15.6% and 18.1% in the second and third years. Predictors of non-persistence were female gender (HR: 1.10; 95% CI: 1.01-1.19), older age (HR: 1.52; 95% CI: 1.31-1.75), primary prevention (HR: 1.10; 95% CI: 1.00-1.20), initiating on low dose (HR: 1.44; 95% CI: 1.07-1.94) or standard dose (HR: 1.56; 95% CI: 1.16-2.10), and no cardiovascular co-medication (HR: 1.19; 95% CI: 1.07-1.33), while patients with four or more other medications were more likely to be persistent. Age < 50 years (OR: 1.47; 95% CI: 1.22-1.77), low socioeconomic status (OR: 1.27; 95% CI: 1.12-1.45) and primary prevention (OR: 1.21; 95% CI: 1.07-1.38) were predictors of non-adherence, while females were more likely to be adherent (OR: 0.87; 95% CI: 0.77-0.98). Conclusion: Non-persistence was the foremost problem in the first year after statin initiation, while non-adherence in persistent patients increased in the second and third years. Pharmacy-based predictors of statin non-persistence were different from predictors of non-adherence among persistent patients.
引用
收藏
页码:1013 / 1019
页数:7
相关论文
共 28 条
[1]   Introduction [J].
不详 .
DIABETES CARE, 2017, 40 :S1-S130
[2]   A Competing Risks Prescription Refill Model of Compliance and Persistence [J].
Barron, T. Ian ;
Bennett, Kathleen ;
Feely, John .
VALUE IN HEALTH, 2010, 13 (06) :796-804
[3]   The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review [J].
Cramer, J. A. ;
Benedict, A. ;
Muszbek, N. ;
Keskinaslan, A. ;
Khan, Z. M. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (01) :76-87
[4]   Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study [J].
de Vries, F. M. ;
Voorham, J. ;
Hak, E. ;
Denig, P. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (06) :482-492
[5]   Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients [J].
de Vries, F. M. ;
Voorham, J. ;
Hak, E. ;
Denig, P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (12) :2197-2206
[6]   Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design [J].
de Vries, F. M. ;
Denig, P. ;
Vegter, S. ;
Bos, H. J. ;
Postma, M. J. ;
Hak, E. .
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (04) :595-602
[7]   A systematic review to assess adherence and persistence with statins [J].
Deshpande, Sohan ;
Quek, Ruben G. W. ;
Forbes, Carol A. ;
de Kock, Shelley ;
Kleijnen, Jos ;
Gandra, Shravanthi R. ;
Simpson, Ross J., Jr. .
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (04) :769-778
[8]   Long-term adherence to statin treatment in diabetes [J].
Donnelly, L. A. ;
Doney, A. S. F. ;
Morris, A. D. ;
Palmer, C. N. A. ;
Donnan, P. T. .
DIABETIC MEDICINE, 2008, 25 (07) :850-855
[9]   Suboptimal statin adherence and discontinuation in primary and secondary prevention populations - Should we target patients with the most to gain? [J].
Ellis, JJ ;
Erickson, SR ;
Stevenson, JG ;
Bernstein, SJ ;
Stiles, RA ;
Fendrick, AM .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 (06) :638-645
[10]   Withdrawal of cerivastatin from the world market [J].
Furberg, CD ;
Pitt, B .
CURRENT CONTROLLED TRIALS IN CARDIOVASCULAR MEDICINE, 2001, 2 (05) :205-207